Promedior Stock

promedior.comHealthcareFounded: 2006Funding to Date: $76MM

Developer of therapeutics designed to treat fibrotic diseases. The company develops a drug discovery platform to regulate the monocyte-derived cell populations that play roles in fibrotic, inflammatory and autoimmune diseases, enabling patients with medicines to cure their diseases.

Register for Details

For more details on financing and valuation for Promedior, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Promedior.

Register Today

Team

Management Team

Richard Jack Ph.D
President, Chief Scientific Officer & Chief Operating Officer
Renu Gupta
Chief Medical Officer
W. Scott Willett Ph.D
Vice President of Biopharmaceutical Development
Nancy Thomason
Chairman
Jason Lettmann
Chief Executive Officer & Board Member
Kieran McCarthy
Vice President of Business Development

Board Members

Geert-Jan Mulder MD
Forbion
Jason Lettmann
Paul Goldenheim MD
Howard Weisman
Nancy Thomason
Augustine Lawlor
John Friedman JD
Easton Capital Investment Group

Other companies like Promedior in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$400.53MM
Sector
 
 
Sector
Last Round Est. Valuation
$1.53B
Sector
Last Round Est. Valuation
$396.01MM